Prokidney Corp (PROK)

• $1.54

  $1.73

  $1.70
  

  9.38%

  Downside

  Day's Volatility :10.95%

  Upside

  1.73%

  
• $1.12

  $4.85

  $1.70
  

  34.12%

  Downside

  52 Weeks Volatility :76.91%

  Upside

  64.95%

  

Returns

What analysts predicted

Upside of 174.71%

• Morgan Stanley - Brokerage Accounts

  11.46%

• Suvretta Capital Management, LLC

  7.41%

• Vanguard Group Inc

  3.15%

• BlackRock Inc

  2.90%

• Bleichroeder LP

  2.07%

• State Street Corp

  0.98%

prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.